熊去氧胆酸治疗原发性胆汁性肝硬化研究进展

Advances in Study of Ursodeoxycholic Acid in the Treatment of Primary Biliary Cirrhosis

原发性胆汁性肝硬化(PBC)是一种慢性肝内胆汁淤积性疾病,好发于中年女性。PBC最常见的死因为肝功能衰竭,这曾是肝移植的首要指征,但有效的治疗已减少了这类患者对肝移植的需求,并使其预期寿命得以延长。熊去氧胆酸(UDCA)是目前较为公认的治疗PBC的药物,但仍存在很大争议。本文就UDCA治疗PBC的作用机制、临床疗效依据、临床应用等方面的研究进展作一综述。

Primary biliary cirrhosis （PBC） is a chronic intrahepatic cholestatic disease that primarily affects middle- aged women. The most common cause of death in these patients is liver failure, which had been the leading indication for liver transplantation. However, effective therapy can reduce the need for liver transplantation in these patients, the life expectancy may be prolonged. Use of ursodeoxveholic acid （UDCA） has been recommended for patients with PBC, although there are still some debates. This article reviewed the advances in the study of UDCA for treating PBC, including mechanism, evidence of clinical effects and clinical applications.